303 related articles for article (PubMed ID: 20460518)
1. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.
Chakravarty D; Nair SS; Santhamma B; Nair BC; Wang L; Bandyopadhyay A; Agyin JK; Brann D; Sun LZ; Yeh IT; Lee FY; Tekmal RR; Kumar R; Vadlamudi RK
Cancer Res; 2010 May; 70(10):4092-101. PubMed ID: 20460518
[TBL] [Abstract][Full Text] [Related]
2. Functional implications of altered subcellular localization of PELP1 in breast cancer cells.
Vadlamudi RK; Manavathi B; Balasenthil S; Nair SS; Yang Z; Sahin AA; Kumar R
Cancer Res; 2005 Sep; 65(17):7724-32. PubMed ID: 16140940
[TBL] [Abstract][Full Text] [Related]
3. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
[TBL] [Abstract][Full Text] [Related]
4. Significance of PELP1 in ER-negative breast cancer metastasis.
Roy S; Chakravarty D; Cortez V; De Mukhopadhyay K; Bandyopadhyay A; Ahn JM; Raj GV; Tekmal RR; Sun L; Vadlamudi RK
Mol Cancer Res; 2012 Jan; 10(1):25-33. PubMed ID: 22086908
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
6. Estradiol-Induced MMP-9 Expression via PELP1-Mediated Membrane-Initiated Signaling in ERĪ±-Positive Breast Cancer Cells.
Pan Y; Wang X; Zhang Y; Qiao J; Sasano H; McNamara K; Zhao B; Zhang D; Fan Y; Liu L; Jia X; Liu M; Song S; Wang L
Horm Cancer; 2020 Apr; 11(2):87-96. PubMed ID: 32037484
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Rajhans R; Nair S; Holden AH; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2007 Jun; 67(11):5505-12. PubMed ID: 17545633
[TBL] [Abstract][Full Text] [Related]
8. Role of PELP1/MNAR signaling in ovarian tumorigenesis.
Dimple C; Nair SS; Rajhans R; Pitcheswara PR; Liu J; Balasenthil S; Le XF; Burow ME; Auersperg N; Tekmal RR; Broaddus RR; Vadlamudi RK
Cancer Res; 2008 Jun; 68(12):4902-9. PubMed ID: 18559538
[TBL] [Abstract][Full Text] [Related]
9. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation.
Manavathi B; Nair SS; Wang RA; Kumar R; Vadlamudi RK
Cancer Res; 2005 Jul; 65(13):5571-7. PubMed ID: 15994929
[TBL] [Abstract][Full Text] [Related]
10. Extranuclear coactivator signaling confers insensitivity to tamoxifen.
Kumar R; Zhang H; Holm C; Vadlamudi RK; Landberg G; Rayala SK
Clin Cancer Res; 2009 Jun; 15(12):4123-30. PubMed ID: 19470742
[TBL] [Abstract][Full Text] [Related]
11. Regulation of aromatase induction by nuclear receptor coregulator PELP1.
Vadlamudi RK; Rajhans R; Chakravarty D; Nair BC; Nair SS; Evans DB; Chen S; Tekmal RR
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):211-8. PubMed ID: 19800002
[TBL] [Abstract][Full Text] [Related]
12. Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.
Nagpal JK; Nair S; Chakravarty D; Rajhans R; Pothana S; Brann DW; Tekmal RR; Vadlamudi RK
Mol Cancer Res; 2008 May; 6(5):851-61. PubMed ID: 18505929
[TBL] [Abstract][Full Text] [Related]
13. Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2.
Jiang K; Yang Z; Cheng L; Wang S; Ning K; Zhou L; Lin J; Zhong H; Wang L; Li Y; Huang J; Zhang H; Ye Q
J Biol Chem; 2013 Aug; 288(34):24590-9. PubMed ID: 23861392
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.
Nair BC; Nair SS; Chakravarty D; Challa R; Manavathi B; Yew PR; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2010 Sep; 70(18):7166-75. PubMed ID: 20807815
[TBL] [Abstract][Full Text] [Related]
15. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
16. Emerging significance of ER-coregulator PELP1/MNAR in cancer.
Nair S; Vadlamudi RK
Histol Histopathol; 2007 Jan; 22(1):91-6. PubMed ID: 17128415
[TBL] [Abstract][Full Text] [Related]
17. Cancer Stem Cell Phenotypes in ER
Truong TH; Hu H; Temiz NA; Hagen KM; Girard BJ; Brady NJ; Schwertfeger KL; Lange CA; Ostrander JH
Mol Cancer Res; 2018 Apr; 16(4):707-719. PubMed ID: 29348189
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
Chakravarty D; Roy SS; Babu CR; Dandamudi R; Curiel TJ; Vivas-Mejia P; Lopez-Berestein G; Sood AK; Vadlamudi RK
Clin Cancer Res; 2011 Apr; 17(8):2250-9. PubMed ID: 21421858
[TBL] [Abstract][Full Text] [Related]
19. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
20. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]